Global Hydronephrosis Therapies Market 2019-2023
Hydronephrosis is a condition when the inside of the kidney gets dilated or stretched and usually analgesics and drugs for kidney stones are used as therapeutics for hydronephrosis.
Technavio’s analysts forecast the Global Hydronephrosis Therapies Market to grow at a CAGR of 9.14% during the period 2019-2023.
Covered in this report
The report covers the present scenario and the growth prospects of the hydronephrosis therapies market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of hydronephrosis across the globe.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report - Global Hydronephrosis Therapies Market 2019-2023
Technavio recognizes the following company as the key player in the global hydronephrosis therapies market: Allergan, F. Hoffmann-La Roche, Novartis, Pfizer, and Teva Pharmaceutical Industries.
Commenting on the report, an analyst from Technavio’s team said: “One trend affecting this market is the increasing awareness of kidney diseases. Kidney diseases are the major causes of hydronephrosis. However, early-stage kidney disease is typically asymptomatic and may not notice any symptoms, which, in turn, leads to low levels of awareness in people with CKD.”
According to the report, one driver influencing this market is the driven by growing prevalence of kidney diseases that result in a higher incidence of hydronephrosis. Hydronephrosis is caused by kidney related diseases such as UTIs, CKDs, and kidney stones. According to the CDC, around 30 million people in the US are affected by CKD, which is likely to augment the growth of the global hydronephrosis treatment market. Furthermore, the increasing prevalence of ESRD, another kidney related disorder, will drive the demand for treatment of hydronephrosis across the period of forecast.
Further, the report states that one challenge affecting this market is the availability of alternate therapies. The growth of the market is impeded by the fact that despite having medications for the treatment of the underlying cause of hydronephrosis, there are several alternative procedures for the management of hydronephrosis.
F. Hoffmann-La Roche
Teva Pharmaceutical Industries